Company intelligence / Profile preview

mir|detect

Bremerhaven, Germany

Ownership: Private
Employees: ~1
Development stage: Other

Overview

The M371-Test demonstrates 100% sensitivity and 100% specificity in clinical validation across multiple qPCR platforms. In follow-up care of testicular cancer patients, the test detects recurrences with 100% sensitivity, superior to classic serum markers.

Therapeutic areas: Oncology
Modalities: Nucleic acid-based in-vitro diagnostics (microRNA detection assay)
Industry: Molecular Diagnostics

Partnerships

High-Tech Gründerfonds (HTGF) - investorBAB Beteiligungs- und Managementgesellschaft Bremen (BBM) - investorGorea Plus d.o.o. - distribution partner (Croatia)EDX Medical - distribution partner (Great Britain and Nordics)Gold Standard Diagnostics - distribution partner (Europe)

Beyond the preview

Go deeper on mir|detect.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mir|detect.

Explore the full profile